Cell kinetics and hormonal receptor status in inflammatory breast carcinoma. Comparison with locally advanced disease

Paradiso, Angelo; Tommasi, Stefania; Brandi, Mario; Marzullo, F; Simone, G.; Lorusso, Vito; Mangia, Anita; Lena, M. De

doi:10.1002/1097-0142(19891101)64:9<1922::aid-cncr2820640927>3.0.co;2-i

Cited by 67 publications

(30 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our series, PR-negative status and ER-and PR-negative status were significantly associated with poor OS as previously reported. 32,33 On multivariate analysis, the strongest prognostic factor was the delivery of HDC with HSCS. Patients who received HDC experienced longer DFS and OS than did patients receiving conventional doses.…”

Section: Resultsmentioning

confidence: 99%

Multivariate analysis of survival in inflammatory breast cancer: impact of intensity of chemotherapy in multimodality treatment

Bertucci

Tarpin

Charafe-Jauffret

et al. 2004

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:The prognosis of inflammatory breast cancer (IBC) is poor. We evaluated clinical and biopathological characteristics that could affect survival in 74 women with nonmetastatic IBC consecutively treated in our institution between 1976 and 2000. Patients received primary anthracycline-based chemotherapy at conventional doses (n ¼ 20) or high-dose chemotherapy (HDC) with haematopoietic stem cell support (HSCS) (n ¼ 54). After chemotherapy, 84% of patients underwent mastectomy, 95% were given radiotherapy and 55% tamoxifen. Immunohistochemistry data (ER, PR, ERBB2, P53) on pre-chemotherapy specimens suggested strong differences between IBC and non-IBC. The rate of pathological complete response to chemotherapy was 26% (27% with HDC and 17% with conventional doses, not significant). No single factor was found predictive of response. With a median follow-up of 48 months after diagnosis, the 5-year projected disease-free survival (DFS) was 24% and overall survival (OS) 41%. In multivariate analysis, the strongest independent prognostic factor was the delivery of HDC. The 5-year DFS and OS of patients were respectively 28 and 50% with HDC and 15 and 18% with conventional chemotherapy. These results and comparisons with other series of patients suggest a role for HDC with HSCS as part of the therapeutic approach in IBC. Further prospective studies are required to confirm it.

show abstract

Section: Resultsmentioning

confidence: 99%

Multivariate analysis of survival in inflammatory breast cancer: impact of intensity of chemotherapy in multimodality treatment

Bertucci

Tarpin

Charafe-Jauffret

et al. 2004

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…MKI67 encodes Ki-67 antigen, a large protein of unknown function that is a classical histopathological marker associated with cell proliferation. Paradiso et al (19) have reported higher proliferative activity (mesuared by [ 3 H]thymidine autoradiographic labeling index) in IBC than in non-IBC.…”

Section: Discussionmentioning

confidence: 99%

Molecular Profiling of Inflammatory Breast Cancer

Bièche

Lerebours

Tozlu

et al. 2004

Clinical Cancer Research

214

158

View full text Add to dashboard Cite

Purpose: Inflammatory breast cancer (IBC) is a rare but particularly aggressive form of primary breast cancer. The molecular mechanisms responsible for IBC are largely unknown.Experimental Design: To obtain further insight into the molecular pathogenesis of IBC, we used real-time quantitative reverse transcription (RT)-PCR to quantify the mRNA expression of 538 selected genes in IBC relative to non-IBC.Results: Twenty-seven (5.0%) of the 538 genes were significantly up-regulated in IBC compared with non-IBC. None were down-regulated. The 27 up-regulated genes mainly encoded transcription factors (JUN, EGR1, JUNB, FOS, FOSB, MYCN, and SNAIL1), growth factors (VEGF, DTR/HB-EGF, IGFBP7, IL6, ANGPT2, EREG, CCL3/ MIP1A, and CCL5/RANTES) and growth factor receptors (TBXA2R, TNFRSF10A/TRAILR1, and ROBO2). We also identified a gene expression profile, based on MYCN, EREG, and SHH, which discriminated subgroups of IBC patients with good, intermediate, and poor outcome.Conclusion: Our study has identified a limited number of signaling pathways that require inappropriate activation for IBC development. Some of the up-regulated genes identified here could offer useful diagnostic or prognostic markers and could form the basis of novel therapeutic strategies.

show abstract

“…IBC is more likely to be hormone receptornegative and HER-2/neu tumor marker-positive than noninflammatory LABC. [24][25][26] Despite improved outcomes due to multimodality therapy for BC in general, survival of women with IBC (5-year survival 41%, median survival 2.9 years) is worse than for LABC (63%, 6.4 years, respectively).…”

Section: Molecular Characteristics Of Ibcmentioning

confidence: 42%

Tipifarnib and farnesyltransferase inhibitors in the treatment of inflammatory breast cancer: is the story over? A review

Dehghan-Paz¹,

Il’yasova²,

Golen³

et al. 2013

ODRR

View full text Add to dashboard Cite

Inflammatory breast cancer (IBC) is a rare but aggressive form of breast cancer with unique clinicopathological features and poor prognosis. Its epidemiology is distinct from noninflammatory locally advanced breast cancer (LABC), which points to different etiology. With the advent of multimodality treatment for LABC, the outcomes for women with IBC have improved, but remain significantly inferior to outcomes for noninflammatory LABC. This review focuses on new research in epidemiology and molecular pathways characteristic for IBC. One of the critical carcinogenic events apparently driving the development and progression of IBC is activation of the RhoC protein, which is a part of the Ras oncogene superfamily. These proteins, like other Ras proteins, require posttranslational prenylation for their activation and transfer to cell membranes. Farnesylation is a common type of prenlyation that can be blocked with a new class of drugs -farnesyltransferase inhibitors. The most advanced farnesyltransferase inhibitor in development, tipifarnib, has been evaluated in Phase II clinical trials as monotherapy and in combination with antihormonal agents and trastuzumab in metastatic and locally advanced breast cancer. A few tumor responses have been observed in these trials, but not enough to warrant a Phase III trial. Potential combinations of tipifarnib with other novel agents targeting enzymes downstream to RhoC are reviewed. Some of these drugs, such as imatinib and crizotinib, are already commercially available. Others like perifosine and anti-vascular endothelial growth factor 3 antibody are currently under development. Innovative trial designs to address this rare type of cancer are discussed.

show abstract

Cell kinetics and hormonal receptor status in inflammatory breast carcinoma. Comparison with locally advanced disease

Cited by 67 publications

References 19 publications

Multivariate analysis of survival in inflammatory breast cancer: impact of intensity of chemotherapy in multimodality treatment

Multivariate analysis of survival in inflammatory breast cancer: impact of intensity of chemotherapy in multimodality treatment

Molecular Profiling of Inflammatory Breast Cancer

Tipifarnib and farnesyltransferase inhibitors in the treatment of inflammatory breast cancer: is the story over? A review

Contact Info

Product

Resources

About